The longitudinal history of medicines innovation: Part Two

November 2, 2023
DNA sequencing

This article was originally published at PharmaPhorum.

The second of a two-part article, CRA’s Life Sciences Practice team, along with experts at The Janssen Pharmaceutical Companies of Johnson & Johnson, recently conducted a landscape review of how complex pharmaceutical innovation happens in practice, leveraging three therapy area case studies: HIV/AIDS, multiple sclerosis, and multiple myeloma.

Overall, our case study research demonstrates that innovation has been the result of collaborative and complementary contributions by biopharmaceutical companies, academic researchers, and public organisations. Such synergistic efforts lead to improved therapies over time, as we learn more about diseases from both basic research and lived experience with approved medicines. Success depends on a high level of clinical and competitive risk-taking to drive innovation forwards and to ensure that patients benefit from technological advances and new treatment options. There remains much more to do in each therapy area, however, the overall story so far is overwhelmingly one of progress.

Key contacts